Please login to the form below

Not currently logged in
Email:
Password:

Teva's Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer.

He joins the Irish biopharma company from Teva, where he served as general manager of its US respiratory division, and prior to that he held senior roles at GlaxSmithKline and Altana.

Amarin’s president and CEO John Thero said: "Mark brings a strong track record of success coupled with valuable experience and proven leadership to our management team to help drive our anticipated expansion.

"We expect Mark's driven, people-oriented, hands-on approach to work well with our existing commercial organisation to help build on our growth.”

Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial. The 8,000-patient study involves its first FDA-approved product, the omega-3 fatty acid-based Vascepa.

21st September 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics